Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a "sell" rating on the biopharmaceutical company's stock.

RGLS has been the topic of a number of other reports. Canaccord Genuity Group reissued a "hold" rating and issued a $11.00 price objective (down from $28.00) on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. Leerink Partners reaffirmed a "market perform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a research report on Thursday, May 1st. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Regulus Therapeutics in a report on Friday, March 14th. Finally, Jones Trading reissued a "hold" rating and set a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $8.50.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock traded up $0.02 during mid-day trading on Friday, reaching $7.86. 306,457 shares of the company were exchanged, compared to its average volume of 883,140. The company has a fifty day simple moving average of $3.02 and a 200-day simple moving average of $1.97. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $8.20. The firm has a market cap of $520.34 million, a PE ratio of -7.34 and a beta of 0.49.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.14. Sell-side analysts anticipate that Regulus Therapeutics will post -0.88 earnings per share for the current year.

Institutional Trading of Regulus Therapeutics

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in Regulus Therapeutics in the third quarter worth about $46,000. Oppenheimer & Co. Inc. purchased a new stake in Regulus Therapeutics in the first quarter worth about $96,000. PEAK6 LLC bought a new position in shares of Regulus Therapeutics during the fourth quarter valued at approximately $95,000. Velan Capital Investment Management LP bought a new position in shares of Regulus Therapeutics during the fourth quarter valued at approximately $111,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Regulus Therapeutics by 193.4% during the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 52,059 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.